Robert Tiballi, DO
Infectious Disease · Elgin, ILNPI 1194757427
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $17,333 of the $19,245 with a category attached, or 90.1%. Takeda Pharmaceuticals U.S.A., Inc. accounts for 92.5% of it on its own, with 15 other manufacturers making up the rest. 2022 is the largest year on record at $17,333, more than ten times the $1,178 reported in 2019. Among infectious disease clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 82 payments — averaging $234.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$18K
- Melinta Therapeutics, LLC$454
- AbbVie$253
- Merck$162
- Gilead$114
- Viiv Healthcare Company$108
- plus $346 from 10 others
What the payments were for
- Consulting fees$17,33390%
- Food & beverage$1,4247%
- Education$4883%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $17,808 |
| Melinta Therapeutics, LLC | 23 | $454 |
| AbbVie | 11 | $253 |
| Merck | 9 | $162 |
| Gilead | 6 | $114 |
| Viiv Healthcare Company | 6 | $108 |
| Johnson & Johnson | 4 | $91 |
| Insmed, Inc. | 4 | $70 |
| Paratek Pharmaceuticals, Inc. | 2 | $47 |
| Shire North American Group Inc | 2 | $34 |
| Philips North America LLC | 1 | $22 |
| Mayne Pharma Commercial LLC | 1 | $20 |
| Amgen | 1 | $19 |
| Nabriva Therapeutics, PLC | 1 | $17 |
| Romark Laboratories, LC | 1 | $13 |
| Cumberland Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DALVANCE$112
How this compares
$19,245 in reported general payments places this provider in the 90th percentile of 368 infectious disease providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 12 | $7,338 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 17 | $1,169 |
| CeftriaxoneCeftriaxone Sodium | 18 | $542 |
| Doxycycline Hyclate | 13 | $109 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 13 | $66 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Elgin
- Frank PalellaChicago$987K
- Jeffrey ShermanDeerfield$527K
- Catherine CreticosChicago$335K
- Babafemi TaiwoChicago$292K
- Beverly ShaChicago$202K
- Chad ZawitzChicago$193K
- Nancy GlickChicago$186K
- Kamaljit SinghChicago$138K
- Jorge ParadaMaywood$128K
- James SullivanChicago$100K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.